Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Rating of “Moderate Buy” from Brokerages

Pyxis Oncology, Inc. (NASDAQ:PYXS) has been given an average rating of “Moderate Buy” by the ten brokerages that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $8.75.

A number of equities research analysts have weighed in on the company. HC Wainwright upped their target price on Pyxis Oncology from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Thursday. Wedbush lifted their price target on Pyxis Oncology from $6.00 to $8.00 and gave the company an “outperform” rating in a research report on Thursday. Wells Fargo & Company boosted their price objective on Pyxis Oncology from $12.00 to $19.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 9th. Leerink Partners cut their price objective on Pyxis Oncology from $9.00 to $7.00 and set an “outperform” rating for the company in a report on Thursday, July 2nd. Finally, Weiss Ratings cut Pyxis Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 30th.

Pyxis Oncology Stock Performance

Pyxis Oncology stock opened at $3.21 on Wednesday. Pyxis Oncology has a 52 week low of $1.03 and a 52 week high of $5.55. The stock has a market cap of $267.75 million, a price-to-earnings ratio of -2.28 and a beta of 1.34. The company’s 50-day moving average price is $3.03 and its two-hundred day moving average price is $2.24.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). Research analysts expect that Pyxis Oncology will post -1.21 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pyxis Oncology

Large investors have recently made changes to their positions in the business. Renaissance Technologies LLC grew its stake in shares of Pyxis Oncology by 22.0% in the 1st quarter. Renaissance Technologies LLC now owns 888,680 shares of the company’s stock worth $1,297,000 after purchasing an additional 160,300 shares during the last quarter. J. Derek Lewis & Associates Inc. acquired a new stake in Pyxis Oncology during the fourth quarter valued at approximately $61,000. XTX Topco Ltd boosted its holdings in Pyxis Oncology by 1,533.0% during the fourth quarter. XTX Topco Ltd now owns 289,033 shares of the company’s stock worth $332,000 after buying an additional 271,334 shares in the last quarter. Toronto Dominion Bank bought a new stake in Pyxis Oncology during the fourth quarter worth approximately $86,000. Finally, Quadrature Capital Ltd acquired a new position in Pyxis Oncology in the fourth quarter worth approximately $116,000. Institutional investors own 39.07% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.